Atherosclerosis: Its Cause and Its Prevention

American Journal of Cardiology

Volumn 98, Issue 11, 2006, Pages 1550-1555

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PENICILLIN G; ROSUVASTATIN;

AGING; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARNIVORE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; DIABETES MELLITUS; DYSLIPIDEMIA; EDITORIAL; FAMILY HISTORY; HERBIVORY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RISK FACTOR;

ATHEROSCLEROSIS; CHOLESTEROL; DIET; HUMANS; RISK FACTORS;

EID: 33751196799     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.10.005     Document Type: Editorial

References (107)

1. Roberts W.C. Atherosclerotic risk factors-are there ten or is there only one?. Am J Cardiol 64 (1989) 552-554
2. Roberts W.C. Factors linking cholesterol to atherosclerotic plaques. Am J Cardiol 62 (1988) 495-499
3. Anitschkow N., and Chalatow S. On experimental cholesterin steatosis and its significance in the origin of some pathological processes. Centralbl f allg Path u path Anat 24 (1913) 1-9
4. Anitschkow N. Experimental atherosclerosis in animals. In: Cowdry E.V. (Ed). In Arteriosclerosis: A Survey of the Problem (1933), Macmillan, New York 271-322
5. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 973-979
6. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F.M., Moye L.A., Goldman S., Flaker G.C., Braunwald E., and Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98 (1998) 839-844
7. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 340 (1999) 115-126
8. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
9. Leary T. Experimental atherosclerosis in the rabbit compared with human (coronary) atherosclerosis. Arch Path 17 (1934) 453-492
10. Leary T. Atherosclerosis, the important form of atherosclerosis, a metabolic disease. Eleventh Ludrig Hektoen Lecture of the Frank Billings Foundation of the Institute of Medicine of Chicago. JAMA 105 (1935) 475-481
11. Keys A. SEVEN COUNTRIES. A Multivariate Analysis of Death and Coronary Heart Disease (1980), Harvard University Press, Cambridge, Massachusetts 381
12. Kannel W.B., Castelli W.P., Gordon T., and McNamara P.M. Serum cholesterol, lipoprotein, and the risk of coronary heart disease: the Framingham study. Ann Intern Med 74 (1971) 1-12
13. Castelli W.P. Epidemiology of coronary heart disease: The Framingham Study. Am J Med 76 2A (1984) 4-12
14. Miettinen M., Turpeinen O., Karvonen M.J., Elosuo R., and Paavilainen E. Effects of cholesterol-lowering diet on mortality from coronary heart-disease and other causes: a twelve-year clinical trial in men and women. Lancet 2 (1972) 835-838
15. Turpeinen O. Effect of cholesterol-lowering diet on mortality from coronary heart disease and other causes. Circulation 59 (1979) 1-7
16. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA 248 (1982) 1465-1477
17. From the Lipid Metabolism-Atherogenesis Branch, National Heart, Lung, and Blood Institute, Bethesda, MD. The Lipid Research Clinics Coronary Primary Prevention Trial Results. 1. Reduction in incidence of coronary heart disease. JAMA 251 (1984) 351-364
18. The Lipid Research Clinics Coronary Primary Prevention Trial Results. 1. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251 (1984) 365-374
19. Frantz Jr. I.D., Dawson E.A., Ashman P.L., Gatewood L.C., Bartsch G.E., Kuba K., and Brewer E.R. Test of effect of lipid lowering by diet on cardiovascular risk: the Minnesota Coronary Survey. Arteriosclerosis 9 (1989) 129-135
20. Scandinavian Simvastatin Survival Study Group. Ramdomised trial of cholesterol lowering in 4444 patients with coronary heart disease; the Scandinavian Simvastatin Survival Study (4S). Lancet 334 (1994) 1383-1389
21. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J., and West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
22. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M.O., Wun C.C., David B.R., Braunwald E., and Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
23. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
24. Downs J.R., Clearfield M., Weis S., Whitney E., Sharpiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto Jr. A.M., and AFCAPD/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 279 (1998) 1615-1622
25. LaRosa J.C., He J., and Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis or randomized controlled trials. JAMA 282 (1999) 2340-2346
26. Gotto Jr. A.M., Whitney E., Stein E.A., Shapiro D.R., Clearfield M., Weis S., Jou J.Y., Langendorfer A., Beere P.A., Watson D.J., Downs Jr., and De Cani J.S. Relation between baseline and on-treatment parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101 (2000) 477-484
27. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360 (2002) 7-22
28. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 361 (2003) 2005-2016
29. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., Mehlsen J., Nieminen M., O'Brien E., Ostergren J., and ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 361 (2003) 1149-1158
30. Collin R., Armitage J., Parish S., Sleight P., Peto R., and Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 363 (2004) 757-767
31. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., Skene A.M., and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
32. Nissen S.E., Tuzcu E.M., Schoenhagen P., Brown B.G., Ganz P., Vogel R.A., Crowe T., Howard G., Cooper C.J., Brodie B., Grines C.L., DeMaria A.N., and REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
33. Nissen S.E., Tuzcu E.M., Schoenhagen P., Crowe T., Sasiela W.J., Tsai J., Orazem J., Magorien R.D., O'Shaughnessy C., Ganz P., and Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38
34. Nissen S.E., Nicholls S.J., Sipahi I., Libby P., Raichlen J.S., Ballantyne C.M., Davignon J., Erbel R., Fruchart J.C., Tardif J., Schoenhagen P., Crowe T., Cain V., Wolski K., Goormastic M., Tuzcu E.M., and ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID Trial. JAMA 295 (2006) E1-E10 13
35. Roberts W.C. We think we are one, we act as if we are one, but we are not one. Am J Cardiol 66 (1990) 1402
36. Steiner P.E. Necropsies on Okinawans. Anatomic and pathologic observations. Arch Pathol 42 (1946) 359-380
37. Eaton S.B., Konner M., and Shostak M. Stone Agers in the fast lane: chronic degenerative diseases in evolutionary perspective. Am J Med 84 (1988) 739-749
38. McCullough M.L., Feskanich D., Stampfer M.J., Rosner B.A., Hu F.B., Hunter D.J., Vriyam J.N., Colditz G.A., and Willett W.C. Adherence to the dietary guidelines for Americans and risk of major chronic disease in women. Am J Clin Nutr 72 (2000) 1214-1222
39. McCullough M.L., Feskanich D., Rimm E.B., Giovannucci E.L., Ascherio A., Variyam J.N., Spiegelman D., Stampfer M.J., and Willett W.C. Adherence to the dietary guidelines for Americans and risk of major chronic disease in men. Am J Clin Nutr 72 (2000) 1223-1231
40. Law M.R., and Morris J.K. By how much does fruit and vegetable consumption reduce the risk of ischaemic heart disease?. Eur J Clin Nutr 52 (1998) 549-556
41. Hu F.B., Stampfer M.J., Manson J.E., Rimm E.B., Colditz G.A., Speizer F.E., Hennekens C.H., and Willett W.C. Dietary protein and risk of ischemic heart disease in women. Am J Clin Nutr 70 (1999) 221-227
42. Obarzanek E., Velletri P.A., and Cutler J.A. Dietary protein and blood pressure. JAMA 275 (1961) 1598-1603
43. Oliver W.J., Cohen E.L., and Neel J.V. Blood pressure, sodium intake and sodium related hormones in the Yanomamo Indians, a "no-salt" culture. Circulation 52 (1975) 146-151
44. Meneely G.R., and Battarbee H.D. High sodium-low potassium environment and hypertension. Am J Cardiol 38 (1976) 768-785
45. Antonios T.T., and MacGregor G.A. Deleterious effects of salt intake other than effects on blood pressure. Clin Exp Pharmacol Physiol 22 (1995) 180-184
46. Stamler J., Caggiula A., Grandits G.A., Kjelsberg M., and Cutler J.A. Relationship to blood pressure of combinations of dietary macronutrients. Findings of the Multiple Risk Factor Intervention Trial (MRFIT). Circulation 94 (1996) 2417-2423
47. MacGregor G.A., and deWardner H.E. Salt, Diet and Health. Neptune's Poisoned Chalice: The Origins of High Blood Pressure (1998), Cambridge University Press, Cambridge, UK 233
48. Washburn S., Burke G.L., Morgan T., and Anthony M. Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. Menopause 6 (1999) 7-13
49. Joshipura K.J., Ascherio A., Manson J.E., Stampfer M.J., Rimm E.B., Speizer F.E., Hennekens C.H., Spiegelman D., and Willett W.C. Fruit and vegetable intake in relation to risk of ischemic stroke. JAMA 282 (1999) 1233-1239
50. Must A., Apadano J., Coakley E.H., Field A.E., Golditz G., and Dietz W.H. The disease burden associated with overweight and obesity. JAMA 282 (1999) 1523-1529
51. O-Dea K., Traianedes K., Ireland P., Niall M., Sadler J., Hopper J., and DeLuise M. The effects of diet differing in fat, carbohydrate, and fiber on carbohydrate and lipid metabolism in type 2 diabetes. J Am Diet Assoc 89 (1989) 1076-1086
52. Feskens E.J., Bowles C.H., and Krombout D. Inverse association between fish intake and risk of glucose intolerance in normoglycemic elderly men and women. Diabetes Care 14 (1991) 935-941
53. Salmeron J., Manson J.E., Stampfer M.J., Colditz G.A., Wing A.L., and Willett W.C. Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women. JAMA 277 (1997) 472-477
54. Mills P.K., Annegers J.R., and Phillips R.L. Animal product consumption and subsequent fatal breast cancer risk among Seventh-day Adventists. Am J Epidemiol 127 (1988) 440-453
55. Block G., Patterson B., and Subar A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer 18 (1992) 1-29
56. Hunter D.J., and Willett W.C. Diet, body size, and breast cancer. Epidemiol Rev 15 (1993) 110-132
57. Ames B.N., Gold L.S., and Willett W.C. The causes and prevention of cancer. Proc Natl Acad Sci USA 92 (1995) 5258-5265
58. Willett W.C., and Hunter D.J. Prospective studies of diet and breast cancer. Cancer 74 3 suppl (1994) 1085-1089
59. Martin-Moreno J.M., Willett W.C., Gorgojo L., Banegas J.R., Rodriguez-Artalejo F., Fernandez-Rodrigues J.C., Maisonneuve P., and Boyle P. Dietary fat, olive oil intake and breast cancer risk. Int J Cancer 58 (1994) 774-780
60. Yuan J.M., Wang Q.S., Ross R.K., Henderson B.E., and Yu M.C. Diet and breast cancer in Shanghai and Tianjin, China. Br J Cancer 71 (1995) 1353-1358
61. Jacobs Jr. D.R., Marquart L., Slavin J., and Kushi L.H. Whole grain intake and cancer: an expanded review and meta-analysis. Nutr Cancer 30 (1998) 85-96
62. Giovannucci E., Rimm E.B., Wolk A., Ascherio A., Stampfer M.J., Colditz G.A., and Willett W.C. Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 58 (1998) 442-447
63. Norrish A.E., Skaeff C.M., Arribas G.L., Sharpe S.J., and Jackson R.T. Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case-control study. Br J Cancer 81 (1999) 1238-1242
64. Holmes M.D., Stampfer M.J., Colditz G.A., Rosner B., Hunter D.H., and Willett W.C. Dietary factors and the survival of women with breast carcinoma. Cancer 86 (1999) 826-835
65. Holmes M.D., Hunter D.J., Colditz G.A., Stampfer M.J., Hankinson S.E., Speizer F.E., Rosner B., and Willett W.C. Association of dietary intake of fat and fatty acids with risk of breast cancer. JAMA 281 (1999) 914-920
66. Zhang S., Hunter D.J., Hankinson S.E., Giovannucci E.L., Rosner B.A., Golditz G.A., Speizer F.E., and Willett W.C. A prospective study of folate intake and the risk of breast cancer. JAMA 281 (1999) 1632-1637
67. Franceschi S., and Favero A. The role of energy and fat in cancers of the breast and colon-rectum in a southern European population. Ann Oncol 10 suppl 6 (1999) 61-63
68. Fuchs C.S., Giovannucci E.L., Colditz G.A., Hunter D.J., Stampfer M.J., Rosner B., Speizer F.E., and Willett W.C. Dietary fiber and the risk of colorectal cancer and adenoma in women. N Engl J Med 340 (1999) 169-176
69. Michels K.B., Giovannuci E., Joshipura K.J., Rosner B.A., Stampfer M.J., Fuchs C.S., Colditz G.A., Speizer F.E., and Willett W.C. Prospective study of fruit and vegetable consumption and incidence of colon and rectal cancers. J Natl Cancer Insti 92 (2000) 1740-1752
70. Sweeney M. Constipation: diagnosis and treatment. Home Care Provid 2 (1997) 250-255
71. Aldoori W.H., Giovannucci E.L., Rockett H.R., Sampson L., Rimm E.B., and Willett W.C. A prospective study of dietary fiber types and symptomatic diverticular disease in men. J Nutr 128 (1998) 714-719
72. Curhan G.C., Willett W.C., Rimm E.B., Spiegelman D., and Stampfer M.J. Prospective study of beverage use and the risk of kidney stones. Am J Epidemiol 143 (1996) 240-247
73. Cummings S.R., Nevitt M.C., Browner W.S., Stone K., Fox K.M., Ensrud K.E., Cauley J., Black D., and Vogt T.M. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332 (1995) 767-773
74. Feskanich D., Willett W.C., Stampfer M.J., and Colditz G.A. Protein consumption and bone fractures in women. Am J Epidemiol 143 (1996) 472-479
75. Munger R.G., Cerhan J.R., and Chiu B.C. Prospective study of dietary protein intake and risk of hip fracture in postmenopausal women. Am J Clin Nutr 69 (1999) 147-152
76. Tucker K.I., Hannan M.T., Chen H., Cupples L.A., Wilson P.W., and Kiel D.P. Potassium, magnesium, and fruit and vegetable intakes are associated with greater bone mineral density in elderly men and women. Am J Clin Nutr 69 (1999) 727-736
77. Sommerburg O., Keunen J.E., Bird A.C., and van Kuijk F.J. Fruits and vegetables that are sources for lutein and zeaxanthin: the macular pigment in human eyes. Br J Ophthalmol 82 (1998) 907-910
78. Jacques P.F. The potential preventive effects of vitamins for cataract and age-related macular degeneration. Int J Vitam Nutr Res 69 (1999) 198-205
79. National Cholesterol Education Program. Report of the NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 148 (1988) 36-39
80. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood cholesterol in Adults (Adult Treatment Panel II). JAMA 269 (1993) 3015-3023
81. Sempos C.T., Cleeman J.L., Carroll M.D., Johnson C.L., Bachorik P.S., Gordon D.J., Burt V.L., Briefel R.R., Brown C.D., Lippel K., and Rifkind B.M. Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. JAMA 269 (1993) 3009-3014
82. Executive Summary of the Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
83. Grundy S.M., Cleeman J.L., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninhake D.B., Pasternak R.C., Smith Jr. S.C., Stone N.J., and Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment panel III guidelines. Circulation 110 (2004) 227-239
84. Brown M.S., and Goldstein J.L. How LDL receptor influence cholesterol and atherosclerosis. Sci Amer 251 (1984) 58-66 5
85. Roberts W.C. Shifting from decreasing risk to actually preventing and arresting atherosclerosis. Am J Cardiol 83 (1999) 816-817
86. Roberts W.C. The underused miracle drugs. The statin drugs are to atherosclerosis what penicillin was to infectious disease. Am J Cardiol 78 (1996) 377-378
87. Roberts W.C. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 80 (1997) 106-107
88. Davidson M.H., Stein E.A., Hunninghake D.B., Ose L., Dujovne C.A., Insull Jr. W., Bertolami M., Weiss S.R., Kastelein J.J., Scott R.S., Campodonico S., Escobar I.D., Schrott H.G., Bays H., Stepanavage M.E., Wu M., Tate A.C., Melino M.R., Kush D., Mercuri M., and Mitchel Y.B. Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia. Nutr Metab Cardiovasc Dis 10 (2000) 253-262
89. Grundy S.M. Can statins cause chronic low-grade myopathy (editorial)?. Am Intern Med 137 (2002) 617-618
90. Ballantyne C.M., Corsini A., Davidson M.H., Holdaas H., Jacobson T.A., Leitersdorf E., Marz W., Reckless J.P., and Stein E.A. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 163 (2003) 553-564
91. Jones P.H., Davidson M.H., Stein E.A., Bays H.E., McKenney J.M., Miller E., Cain V.A., and Blasetto J.W. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR Trial). Am J Cardiol 92 (2003) 152-160
92. Thompson P.D., Clarkson P., and Karas R.H. Statin-associated myopathy. JAMA 289 (2003) 1681-1690
93. Sheperd J., Hunninghake D.B., Stein E.A., Kastelein J.J.P., Harris S., Pears J., and Hutchinson H.G. Safety of Rosuvastatin. Am J Cardiol 94 (2004) 882-888
94. Ballantyne C.M., Blazing M.A., King T.R., Brady W.E., and Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 93 (2004) 1487-1494
95. Grundy S.M. The issue of statin safety: where do we stand?. Circulation 111 (2005) 3016-3019
96. Alsheikh-Ali A.A., Ambrose M.S., Kuvin J.T., and Karas R.H. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 111 (2005) 3051-3057
97. Waters D.D. Safety of high-dose atorvastatin therapy. Am J Cardiol 96 suppl (2005) 69F-75F
98. Davidson M.H., Clark J.A., Glass L.M., and Kanumalla A. Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol 97 suppl (2006) 32C-43C
99. Thompson P.D., Clarkson P.M., and Rosenson R.S. An assessment of statin safety by muscle experts. Am J Cardiol 97 suppl (2006) 69C-76C
100. Cohen D.E., Anania F.A., and Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 97 suppl (2006) 77C-81C
101. Kasiske B.L., Wanner C., and O'Neill W.C. An assessment of statin safety by nephrologists. Am J Cardiol 97 suppl (2006) 82C-85C
102. McKenney J.M., Davidson M.H., Jacobson T.A., and Guyton J.R. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 97 suppl (2006) 89C-94C
103. Ferdinand K.C., Clark L.T., Watson K.E., Neal R.C., Brown C.D., Kong B.W., Barnes B.O., Cox W.R., Zieve F.J., Isaacsohn J., Ycas J., Sager P.T., Gold A., and ARIES Study Group. Comparison of efficiacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am J Cardiol 97 (2006) 229-235
104. Jones P.H., and Davidson M.H. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 95 (2005) 120-122
105. Ornish D. Can life-style changes reverse coronary atherosclerosis?. Hosp Pract 26 5 (1991) 123-126 129-132
106. Leaf A. Dietary prevention of coronary heart disease: The Lyon Diet Heart Study. Circulation 99 (1999) 733-735
107. Denke M.A. Diet, lifestyle, and nonstatin trials: review of time to benefit. Am J Cardiol 96 suppl (2005) 3F-10F